262 related articles for article (PubMed ID: 29300876)
1. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
[TBL] [Abstract][Full Text] [Related]
2. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.
Plennevaux E; Sabchareon A; Limkittikul K; Chanthavanich P; Sirivichayakul C; Moureau A; Boaz M; Wartel TA; Saville M; Bouckenooghe A
Vaccine; 2016 May; 34(24):2707-12. PubMed ID: 27102820
[TBL] [Abstract][Full Text] [Related]
3. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
[TBL] [Abstract][Full Text] [Related]
4. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
[TBL] [Abstract][Full Text] [Related]
5. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
7. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
Savarino SJ; Bonaparte M; Wang H; Dayan GH; Forrat R; Zhu M; Hodge S; Ataman-Önal Y; DiazGranados CA
Lancet Microbe; 2022 Jun; 3(6):e427-e434. PubMed ID: 35659904
[TBL] [Abstract][Full Text] [Related]
8. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
9. Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
El Fezzazi H; Branchu M; Carrasquilla G; Pitisuttithum P; Perroud AP; Frago C; Coudeville L
Am J Trop Med Hyg; 2017 Dec; 97(6):1898-1903. PubMed ID: 29141713
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
13. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
16. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
L'Azou M; Moureau A; Sarti E; Nealon J; Zambrano B; Wartel TA; Villar L; Capeding MR; Ochiai RL; ;
N Engl J Med; 2016 Mar; 374(12):1155-66. PubMed ID: 27007959
[TBL] [Abstract][Full Text] [Related]
18. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
[TBL] [Abstract][Full Text] [Related]
19. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
20. Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule.
Coronel D; García-Rivera EJ; Rivera M; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Zhao J; Tila M; Jackson N; Zambrano B; Noriega F
Pediatr Infect Dis J; 2019 May; 38(5):e90-e95. PubMed ID: 30986790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
